Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)

NCT ID: NCT03807843

Last Updated: 2022-09-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 41 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-07-16
• Study Completion Date: 2021-05-13

Brief Summary

Safety and immunogenicity of the investigational V184 chikungunya vaccine will be tested in participants with history of chikungunya infection. Initially 21 to 50 year old participants will be enrolled; after favorable review of safety data, participants aged 51 to 65 will be enrolled.

Detailed Description

This will be a randomized double-blind interventional clinical study. This study proposes to evaluate the safety and immunogenicity of the investigational V184 live recombinant measles-vectored chikungunya vaccine delivered in 2 vaccinations, 28 days apart compared with saline placebo. After providing informed consent, individuals will be screened for eligibility including verification of previous exposure to chikungunya virus. They will then be randomized in a double-blind fashion to receive either V184 or saline placebo in a 1:1 ratio.

Conditions

Chikungunya Virus Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

V184

Participants will receive 2 vaccinations with V184 administered via intramuscular (IM) injection at 5 × 10\^5 Tissue Culture Infectious Dose (TCID50) per dose on Days 0 and 28.

Group Type: EXPERIMENTAL

V184

Intervention Type: BIOLOGICAL

Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.

Placebo

Participants will receive 2 injections of sterile physiological saline administered via IM injection on Days 0 and 28.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Sterile physiological saline for IM injection

Interventions

V184

Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins. Liquid frozen, life attenuated, measles vectored V184 vaccine administered via IM injection at 5 × 10\^5 TCID50 (+/- 0.5 log) per dose.

Intervention Type: BIOLOGICAL

Placebo

Sterile physiological saline for IM injection

Intervention Type: OTHER

Other Intervention Names

MV-CHIK; MV-CHIK vaccine; MV-CHIK/DP (drug product)

Eligibility Criteria

Inclusion Criteria

• Previous infection with chikungunya as verified by a serum immunoassay.
• Able to provide informed consent.
• Available and accessible for the duration of the trial.
• Able and willing to comply with all requirements of the study.
• For women of childbearing potential, willing to practice adequate contraception for the duration of the study.
• Medical history and physical examination findings are considered normal or not clinically significant in the opinion of the Investigator, which includes resolution of any arthralgias that may have occurred during prior chikungunya infection, as well as the absence of synovitis.
• Laboratory values are considered normal or not clinically significant in the opinion of the Investigator. If laboratory screening tests are out of the normal reference range and of potential clinical significance, the test(s) may be repeated up to 2 times (a total of 3 per screening evaluation) at the discretion of the Investigator, and the repeat values and their potential clinical significance will be used to determine eligibility.
• History of immunity to measles. For persons born after 1957, this will be established by a history of compliance with vaccination policies that included measles vaccination or known vaccination as an adult at least one month before they are randomized. Volunteers born before 1957 will be presumed to have immunity to measles based on natural exposure in accordance with US Centers for Disease Control and Prevention (CDC) guidelines [McLean 2013].

Exclusion Criteria

• Taking medication or other treatment for unresolved symptoms attributed to a previous chikungunya virus infection.
• Prior receipt of any investigational chikungunya or other alphavirus vaccine. To date, no alphavirus vaccines have been commercially available in the United States.
• Recent infection:

• self-limited upper respiratory infections until afebrile without medication for >1 week;
• chikungunya unless/until asymptomatic (other than mild subjective symptoms not requiring treatment) for >3 months;
• non-recurrent upper respiratory or urinary tract infections successfully treated with antibiotics, until asymptomatic for 1 month after full antibiotic course has been completed.
• History of an acute allergic or anaphylactic reaction to any vaccine.
• History of an immunosuppressive disorder (such as human immunodeficiency virus [HIV] infection, Common Variable Immune Deficiency), chronic infection (such as chronic hepatitis B or C), autoimmune disease (such as rheumatoid arthritis, systemic lupus erythematosus (SLE), autoimmune thyroid disease), or any medical condition that, in the opinion of the Investigator, could lead to an atypical immune response to the vaccine.
• History of moderate or severe non-traumatic arthritis or arthralgia within 3 months of the Screening Visit.
• Recent (within 30 days), current or anticipated use of any immunosuppressive or immune modifying medication including corticosteroids (excluding nasal, ophthalmic, and other topical preparations).
• Other vaccination or planned vaccination within 4 weeks of either study dose (seasonal influenza vaccine excepted).
• Receipt or planned receipt of blood products including immunoglobulins within 120 days of the Screening Visit.
• Pregnant or lactating or planning pregnancy during the trial.
• Known alcohol or other substance abuse that in the opinion of the Investigator affects the ability or willingness of the participant to understand and comply with the study protocol.
• Participation in another clinical study within the past 30 days in which the participant was exposed to an investigational product (pharmaceutical product or placebo or device) or planned participation in another interventional clinical study while participating in this study.
• Relevant history of any medical condition that, in the opinion of the Investigator, may interfere with the safety of the participant or aims of the study.
• History of neoplastic disease (excluding successfully treated non-melanoma skin cancer or cervical intraepithelial neoplasia) within the past 5 years or a history of any hematological malignancy.
• Behavioral or psychiatric disease or cognitive impairment that in the opinion of the Investigator affects the ability or willingness of the participant to understand and comply with the study protocol.
• Non-consent to storage of blood specimens for future research.
• Persons in direct relationship with the Sponsor or its contracted service providers, the contract research organisation (CRO) or its subcontractors, the Investigator, or study site staff. Direct relationship includes first degree relatives or dependents (children, spouse/partner, siblings or parents), as well as employees (site or Sponsor).

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Walter Reed Army Institute of Research (WRAIR)

FED

Sponsor Role: collaborator

Themis Bioscience GmbH

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

San Juan Hospital, Research Unit

San Juan, Puert Rico, Puerto Rico

Countries

Puerto Rico

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

MV-CHIK-206

Identifier Type: OTHER

Identifier Source: secondary_id

V184-006

Identifier Type: -

Identifier Source: org_study_id